Christopher Contag

Dr. Christopher Contag

orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2004 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
CCCatherine M Cowan
Catherine M Cowan
YSYun-Ying Shi
Yun-Ying Shi
OAOliver O Aalami
Oliver O Aalami
YCYu-Fen Chou
Yu-Fen Chou
CMCarina Mari
Carina Mari
MLMichael T Longaker
Michael T Longaker

10 October 2004 in Nature
Verified
Journal Article
Closed access
CSCatherine M. Shachaf
Catherine M. Shachaf
AKAndrew M. Kopelman
Andrew M. Kopelman
CAConstadina Arvanitis
Constadina Arvanitis
ÅKÅsa Karlsson
Åsa Karlsson
SBShelly Beer
Shelly Beer
DFDean W. Felsher
Dean W. Felsher

1 August 2002 in Annual Review of Biomedical Engineering
Verified
Journal Article
Closed access
CCChristopher Contag
Christopher Contag
MBMichael H. Bachmann
Michael H. Bachmann
▪ Abstract To advance our understanding of biological processes as they occur in living animals, imaging strategies have been developed and refined that reveal cellular and molecular features of biology and disease in real time. One rapid and accessible technology for in vivo analysis employs internal biological sources of light emitted from luminescent enzymes, luciferases, to label genes and cells. Combining this reporter system with the new generation of charge coupled device (CCD) cameras that detect the light transmitted through the animal's tissues has opened the door to sensitive in vivo measurements of mammalian gene expression in living animals. Here, we review the development and application of this imaging strategy, in vivo bioluminescence imaging (BLI), together with in vivo fluorescence imaging methods, which has enabled the real-time study of immune cell trafficking, of various genetic regulatory elements in transgenic mice, and of in vivo gene transfer. BLI has been combined with fluorescence methods that together offer access to in vivo measurements that were not previously available. Such studies will greatly facilitate the functional analysis of a wide range of genes for their roles in health and disease.

1 November 1995 in Molecular Microbiology
Verified
Journal Article
Open access
PDF file
CCChristopher Contag
Christopher Contag
PCPamela R. Contag
Pamela R. Contag
JMJames I. Mullins
James I. Mullins
SSStanley D. Spilman
Stanley D. Spilman
DSDavid K. Stevenson
David K. Stevenson
DBDavid A. Benaron
David A. Benaron
The study of pathogenic is often limited to ex vivo assays and cell‐culture correlates. A greater understanding of infectious diseases would be facilitated by in vivo analyses. Therefore, we have developed a method for detecting bacterial pathogens in a living host and used this method to evaluate disease processes for strains of Salmonella typhimurium that differ in their virulence for mice. Three strains of Salmonella were marked with bioluminescence through transformation with a plasmid conferring constitutive expression of bacterial luciferase. Detection of photons transmitted through tissues of animals infected with bioluminescent Salmonella allowed localization of the bacteria to specific tissues. In this manner progressive infections were distinguished from those that were persistent or abortive. We observed patterns of bio‐luminescence that suggested the caecum may play a pivotal role in Salmonella pathogenesis. In vivo efficacy of an antibiotic was monitored using this optical method. This study demonstrates that the real time non‐invasive analyses of pathogenic events and pharmacological monitoring can be performed in vivo.

1 October 1997 in Photochemistry and Photobiology
Verified
Journal Article
Closed access
PDF file
CCChristopher Contag
Christopher Contag
SSStanley D. Spilman
Stanley D. Spilman
PCPamela R. Contag
Pamela R. Contag
MOMasafumi Oshiro
Masafumi Oshiro
BEBrian Eames
Brian Eames
DBDavid A. Benaron
David A. Benaron

1 July 2006 in Blood
Verified
Journal Article
Open access
PDF file
RZRobert Zeiser
Robert Zeiser
VNVu H. Nguyen
Vu H. Nguyen
ABAndreas Beilhack
Andreas Beilhack
MBMartin Buess
Martin Buess
SSStephan Schulz
Stephan Schulz
RNRobert S. Negrin
Robert S. Negrin
CD4+CD25+ regulatory T (Treg) cells control immunologic tolerance and antitumor immune responses. Therefore, in vivo modification of Treg function by immunosuppressant drugs has broad implications for transplantation biology, autoimmunity, and vaccination strategies. In vivo bioluminescence imaging demonstrated reduced early proliferation of donor-derived luciferase-labeled conventional T cells in animals treated with Treg cells after major histocompatibility complex mismatch bone marrow transplantation. Combining Treg cells with cyclosporine A (CSA), but not rapamycin (RAPA) or mycophenolate mofetil (MMF), suppressed Treg function assessed by increased T-cell proliferation, graft-versus-host disease (GVHD) severity, and reduced survival. Expansion of Treg and FoxP3 expression within this population was lowest in conjunction with CSA, suggesting that calcineurin-dependent interleukin 2 (IL-2) production is critically required for Treg cells in vivo. The functional defect of Treg cells after CSA exposure could be reversed by exogenous IL-2. Further, the Treg plus RAPA combination preserved graft-versus-tumor (GVT) effector function against leukemia cells. Our data indicate that RAPA and MMF rather than CSA preserve function of Treg cells in pathologic immune responses such as GVHD without weakening the GVT effect. (Blood. 2006;108:390-399)